Trogarzo® (ibalizumab-uiyk) injection Trogarzo® (ibalizumab) is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. Trogarzo® belongs to the CD4-directed post-attachment HIV-1 inhibitor class of antiretrovirals. In the United States (US), Trogarzo® is approved, in combination with …Lire la suite


EGRIFTA® (tesamorelin for injection) EGRIFTA® (tesamorelin for injection) is approved in the United States and Canada for the reduction of excess abdominal fat in people living with HIV who have lipodystrophy. Lipodystrophy affects the redistribution of fat that includes the accumulation and loss of fat in certain parts of the human body. The excess fat …Lire la suite


EGRIFTA SVTM (tesamorelin for injection) EGRIFTA SVTM is a new formulation of tesamorelin which requires a smaller volume of administration and a smaller needle compared to the original formulation. EGRIFTA SVTM comes in a single vial, instead of two, and can be stored at room temperature.   EGRIFTA SVTM (tesamorelin for injection) is approved in the United States …Lire la suite